This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. SABS, CRIS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, and UTHRShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Its Competitors SAB Biotherapeutics Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Cytori Therapeutics (NASDAQ:CYTX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Is CYTX or SABS more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Cytori Therapeutics' net margin of -242.60%. SAB Biotherapeutics' return on equity of -153.92% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytori Therapeutics-242.60% -272.70% -56.23% SAB Biotherapeutics N/A -153.92%-89.16% Which has better valuation and earnings, CYTX or SABS? Cytori Therapeutics has higher revenue and earnings than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytori Therapeutics$3.67M4.96-$12.63MN/AN/ASAB Biotherapeutics$1.32M18.30-$34.10M-$4.00-0.58 Which has more risk and volatility, CYTX or SABS? Cytori Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Do analysts rate CYTX or SABS? SAB Biotherapeutics has a consensus price target of $9.75, suggesting a potential upside of 320.26%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00SAB Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do insiders & institutionals hold more shares of CYTX or SABS? 2.6% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 0.7% of Cytori Therapeutics shares are owned by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor CYTX or SABS? In the previous week, Cytori Therapeutics' average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score. Company Overall Sentiment Cytori Therapeutics Neutral SAB Biotherapeutics Neutral SummarySAB Biotherapeutics beats Cytori Therapeutics on 9 of the 13 factors compared between the two stocks. Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.20M$69.32M$6.12B$10.63BDividend YieldN/AN/A5.70%4.74%P/E RatioN/A10.4285.6827.43Price / Sales4.9633.04623.15138.97Price / CashN/A18.4137.7861.77Price / Book2.3514.5813.146.74Net Income-$12.63M-$26.69M$3.30B$276.22M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/A$0.82-7.7%N/A-31.6%$18.20M$3.67M0.0037Gap DownHigh Trading VolumeSABSSAB Biotherapeutics3.6754 of 5 stars$2.01flat$9.75+385.1%-14.6%$21.29M$1.32M-0.51140CRISCuris1.7849 of 5 stars$1.66-0.3%$17.00+927.2%-67.7%$20.94M$10.91M-0.3460Positive NewsAnalyst ForecastBOLTBolt Biotherapeutics2.5111 of 5 stars$5.76+8.3%$47.50+724.7%-53.7%$11.05M$4.17M-0.2290Positive NewsAnalyst ForecastAMGNAmgen4.5623 of 5 stars$300.84+6.6%$309.70+2.9%-6.9%$161.78B$33.42B24.5728,000Positive NewsAnalyst UpgradeGILDGilead Sciences4.8857 of 5 stars$112.34+1.2%$117.17+4.3%+38.3%$139.35B$28.86B22.3717,600Positive NewsAnalyst ForecastVRTXVertex Pharmaceuticals4.8015 of 5 stars$406.27+3.7%$493.81+21.5%-8.5%$104.22B$11.42B29.066,100Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.7529 of 5 stars$608.99+8.3%$817.67+34.3%-41.4%$64.47B$14.20B15.3315,106Positive NewsAnalyst ForecastALNYAlnylam Pharmaceuticals4.0627 of 5 stars$461.92+1.3%$439.58-4.8%+72.3%$60.49B$2.46B-186.832,230Analyst ForecastBIIBBiogen4.5908 of 5 stars$151.51+8.2%$182.04+20.1%-17.0%$22.13B$9.68B14.437,605Analyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.3366 of 5 stars$435.88+4.0%$449.57+3.1%+30.6%$19.72B$2.88B17.061,305Analyst ForecastInsider Trade Related Companies and Tools Related Companies SABS Competitors CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
